← Back to Screener
DBV Technologies S.A. (DBVT)
Price$16.59
Value ScoreF
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)16.89%
Price vs S&P 500 (4W)-18.18%
VGM Score41.78
Market Capitalization$889.78M
All Metrics
Book Value / Share (Quarterly)$0.72
P/TBV (Annual)4.52x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)5.18%
Cash Flow / Share (Quarterly)$-0.51
Price vs S&P 500 (YTD)-22.98%
Gross Margin (TTM)93.12%
Net Profit Margin (TTM)-2611.00%
EPS (TTM)$-1.07
10-Day Avg Trading Volume1.43M
EPS Excl Extra (TTM)$-1.07
Revenue Growth (5Y)-12.95%
EPS (Annual)$-1.05
ROI (Annual)-83.94%
Gross Margin (Annual)86.43%
Net Profit Margin (5Y Avg)-1904.48%
Cash / Share (Quarterly)$0.82
Revenue Growth QoQ (YoY)115.98%
ROA (Last FY)-63.05%
Revenue Growth TTM (YoY)35.77%
EBITD / Share (TTM)$-0.97
ROE (5Y Avg)-140.82%
Operating Margin (TTM)-2606.65%
Cash Flow / Share (Annual)$-0.51
P/B Ratio6.08x
P/B Ratio (Quarterly)4.52x
Net Income / Employee (Annual)$-1,177,200
EV / Revenue (TTM)148.63x
Net Interest Coverage (TTM)-581.44x
ROA (TTM)-78.14%
EPS Incl Extra (Annual)$-1.05
Current Ratio (Annual)3.67x
Quick Ratio (Quarterly)3.62x
3-Month Avg Trading Volume1.10M
52-Week Price Return86.41%
Revenue / Employee (TTM)$45,100
Tangible BV / Share (Quarterly)$0.72
P/S Ratio (Annual)181.93x
Asset Turnover (Annual)0.02x
52-Week High$4.50
Operating Margin (5Y Avg)-1921.02%
EPS Excl Extra (Annual)$-1.05
CapEx CAGR (5Y)-27.90%
Tangible BV CAGR (5Y)-3.85%
26-Week Price Return24.81%
Quick Ratio (Annual)3.62x
13-Week Price Return-24.05%
Total Debt / Equity (Annual)0.04x
Current Ratio (Quarterly)3.67x
Enterprise Value$837.69M
Revenue / Share Growth (5Y)-27.98%
Asset Turnover (TTM)0.03x
Book Value / Share Growth (5Y)-28.16%
Revenue / Employee (Annual)$45,100
Inventory Turnover (Annual)0.55x
Pretax Margin (Annual)-2602.29%
Cash / Share (Annual)$0.82
3-Month Return Std Dev48.57%
Gross Margin (5Y Avg)88.12%
Net Income / Employee (TTM)$-1,177,200
ROE (Last FY)-87.19%
Net Interest Coverage (Annual)-52.83x
EPS Basic Excl Extra (Annual)$-1.05
Receivables Turnover (TTM)22.36x
Total Debt / Equity (Quarterly)0.04x
EPS Incl Extra (TTM)$-1.07
Receivables Turnover (Annual)5.12x
ROI (TTM)-109.34%
P/S Ratio (TTM)181.93x
Pretax Margin (5Y Avg)-1903.50%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$0.72
Price vs S&P 500 (52W)62.04%
Year-to-Date Return-15.62%
5-Day Price Return-11.92%
EPS Normalized (Annual)$-1.05
ROA (5Y Avg)-76.57%
Net Profit Margin (Annual)-2611.00%
Month-to-Date Return-15.12%
Cash Flow / Share (TTM)$-0.78
EBITD / Share (Annual)$-1.02
Operating Margin (Annual)-2606.65%
LT Debt / Equity (Annual)0.59x
ROI (5Y Avg)-120.91%
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$-1.07
P/TBV (Quarterly)4.52x
P/B Ratio (Annual)4.52x
Inventory Turnover (TTM)0.83x
Pretax Margin (TTM)-2602.29%
Book Value / Share (Annual)$0.72
Price vs S&P 500 (13W)-32.30%
Beta0.51x
Revenue / Share (TTM)$0.04
ROE (TTM)-115.44%
52-Week Low$1.45
vGradeF
gGradeC
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DBVTDBV Technologies S.A. | F | C | C | $16.59 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
DBV Technologies is a clinical-stage biopharmaceutical company developing Viaskin, a proprietary patch-based immunotherapy platform that delivers therapeutics through intact skin for immune-mediated disorders. The company's lead program, Viaskin Peanut, targets peanut allergies, with earlier-stage candidates in milk allergy and eosinophilic esophagitis. This epicutaneous delivery approach represents a differentiated mechanism to address significant unmet needs in food allergy treatment.